Johnson & Johnson stock price, JNJ

Johnson & Johnson stock chart:



Johnson & Johnson close price: 123.64

Stock price forecast:

DOWN TO -0.07%
Target: 123.55

Total forecasts: 82
Reached: 1 (1.22%)

Total Win: 3.93 (3.13%)

DaysForecastsReached%Reached points%InvestedUnreached%Total%
908311.20%3.930.04%10,194.8856.400.55%60.330.58%
303100.00%0.000.00%3,829.61-3.23-0.08%-3.23-0.08%
141500.00%0.000.00%1,854.600.000.00%0.000.00%
7800.00%0.000.00%989.120.000.00%0.000.00%

Showing 1-10 of 569 items.
Date of ForecastStock PriceTarget PriceForecast Reached Date
2017-05-29123.64123.550000-00-00
2017-05-28123.64123.540000-00-00
2017-05-27123.64123.540000-00-00
2017-05-26123.64123.530000-00-00
2017-05-25123.64123.530000-00-00
2017-05-24123.64123.510000-00-00
2017-05-23123.64123.50000-00-00
2017-05-22123.64123.50000-00-00
2017-05-21123.64123.50000-00-00
2017-05-20123.64123.50000-00-00

Johnson & Johnson latest news:


  • 05/26/2017 14:01:52

    Home Depot, Johnson & Johnson Drag DJIA Lower Friday


  • 05/23/2017 10:01:55

    Alexion stock plummets 9% after top management shake-up

    Alexion Pharmaceuticals Inc. shares dropped 9.2% to $104.89 in very active morning trade Tuesday after the company announced departures of its chief commercial officer, chief financial officer and two executive vice presidents. The company just appointed a new chief executive officer, Ludwig Hantson, in late March, and CFO Dave Anderson started at the company in December. "These changes appear to be the plan of the recently appointed new CEO, Ludwig Hantson, and we believe signal his intention to make a complete break with the company's past leadership," said Leerink analyst Geoffrey Porges, adding that after the shake-up, "none of the management team that built the Soliris business, or presided over the value-destroying Synageva deal in 2015, remain in place...These changes are not a complete surprise, given the signals that have been coming from new CEO, but will alarm many investors given the concern that there may be other 'shoes to drop' in terms of disclosure of additional underlying issues with the core business and operations." Still, Porges reiterated an outperform rating for Alexion. Two executives, CCO Carsten Thiel and Executive Vice President, Chief Human Resources Officer Clare Carmichael, will be leaving the company "to pursue new opportunities" starting June 1, the company said. Thiel will be replaced by Brian Goff, who has worked in biopharma for more than 25 years at companies including Johnson & Johnson and Baxter . CFO Anderson will resign at the end of August and Executive Vice President, Head of Research & Development Martin Mackay will be retiring at the end of this year, the company said, with searches underway for the open positions and a new head of human resources. Alexion shares have dropped 19.8% over the last three months, compared with a 1.5% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 05/16/2017 16:14:45

    U.S. FDA warns of foot, leg amputations with J&J diabetes drug

    May 16 (Reuters) - Johnson & Johnson is required to add new warnings to its diabetes drug, Invokana, about the risk of foot and leg amputations, the U.S. Food and Drug Administration said on Tuesday.

  • 05/15/2017 09:29:09

    Johnson & Johnson's stock jumps after analyst turns bullish for first time in 4 years

    Shares of Johnson & Johnson jumped 1.9% in midday trade Monday, after J.P. Morgan turned bullish on the health care products company for the first time in 4 years on the belief that the recent weakness in fundamentals is on the verge of bottoming. Analyst Michael Weinstein raised his rating to overweight after being at neutral since April 2013. He listed his stock price target to $140, which is about 11% above current levels, from $133. J&J's stock had fallen 4.1% since the March 15 record close through Friday, with most of the losses coming with the selloff after disappointing first-quarter results on April 18. Weinstein expects the second quarter to be "just as challenging," but said he believes sentiment, which is currently "particularly negative," will begin to turn as fundamentals improve in the second half of the year. "We recognize that this is a notably contrarian call today," Weinstein wrote in a note to clients. "But...once J&J gets the second quarter behind it, [year-over-year comparisons] ease considerably, new products should get approved, and clinical read-outs become potential catalysts for an improving pharma business and a reacceleration of top-line growth." The stock has gained 11% over the past 12 months, while the Dow Jones Industrial Average has rallied 20%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 05/04/2017 19:53:50

    UPDATE 2-J&J ordered to pay $110 million in U.S. talc-powder trial

    May 4 (Reuters) - Johnson & Johnson on Thursday was ordered by a Missouri jury to pay over $110 million to a Virginia woman who says she developed ovarian cancer after decades of using of its talc-based products for feminine hygiene.

  • 05/04/2017 18:54:41

    J&J ordered to pay $110 million in U.S. talc-powder trial

    (Reuters) - Johnson & Johnson on Thursday was ordered by a Missouri jury to pay over $110 million to a Virginia woman who says she developed ovarian cancer after decades of using of its talc-based products for feminine hygiene.

  • 04/27/2017 09:05:38

    BRIEF-J&J increase qtrly dividend by 5 pct to $0.84 per share

    * Johnson & johnson announces dividend increase of 5.0 percent

  • 04/18/2017 14:36:22

    Johnson & Johnson, Goldman sneeze and stocks catch a cold

    US stocks fall, with health care and bank stocks down the most after poor first-quarter results from Johnson & Johnson and Goldman Sachs

  • 04/18/2017 14:21:55

    Goldman Sachs, J&J pull Wall Street lower

    NEW YORK (Reuters) - The S&P 500 fell for the fourth time in five sessions on Tuesday, weighed down by a drop in Goldman Sachs and Johnson & Johnson following their quarterly results, while geopolitical tensions added to investor caution.

  • 04/18/2017 14:06:33

    Wall St. loses ground as Goldman, J&J slump

    NEW YORK (Reuters) - The S&P 500 fell for the fourth time in five sessions on Tuesday, weighed down by declines in Goldman Sachs and Johnson & Johnson following their quarterly results, while geopolitical tensions added to investor caution.

  • 04/18/2017 14:02:03

    U.S. stocks closer lower as Goldman, J&J disappoint with their results

    U.S. stocks closed lower on Tuesday, pressured after a number of key companies disappointed with their quarterly results, renewing concerns that the market's valuation may not be supported by economic activity. The Dow Jones Industrial Average fell 113 points, or 0.6%, to 20,524. The S&P 500 lost 6.8 points to 2,342, a drop of 0.3%. The Nasdaq Composite Index fell 7 points to 5,849, a drop of 0.1%. Among the biggest drags on the day was Goldman Sachs Group Inc. , which fell 4.7% after its results fell short of analyst forecasts. Johnson & Johnson lost 3.1%; the company posted a drop in sales in the first quarter. Both are Dow components, accounting for the outsized loss in the blue-chip average. Separately, Netflix Inc. shed 2.6% on concerns about the company's ability to attract and retain new users. While major indexes ended off their lows of the session, market participants have been looking to corporate earnings to justify a multimonth rally in equities that had taken stock benchmarks to repeated records, though the rally has stalled as doubts about valuations pile up and amid concerns over President Donald Trump's ability to quickly implement his economic agenda.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 04/18/2017 12:20:02

    Wall Street falls as Goldman, J&J weigh

    NEW YORK (Reuters) - U.S. stocks declined on Tuesday, weighed down by a drop in Goldman Sachs and Johnson & Johnson in the wake of their quarterly results, while geopolitical tensions continued to fuel investor caution.

  • 04/18/2017 11:39:38

    Sharp losses for health care stocks, banks pull indexes down

    US stocks are falling as Johnson & Johnson and Cardinal Health put pressure on health care companies and weak results from Goldman Sachs affect banks

  • 04/18/2017 10:56:14

    Wall Street down as Goldman, J&J's results disappoint

    (Reuters) - U.S. stocks fell further in midday trading on Tuesday as corporate heavyweights Goldman Sachs and Johnson & Johnson disappointed investors with their quarterly results, while geopolitical tensions continued to weigh on market sentiment.

  • 04/18/2017 09:32:42

    J&J first quarter revenue misses estimates; new forecast includes Actelion

    (Reuters) - Johnson & Johnson on Tuesday reported disappointing pharmaceutical and consumer product sales as revenue missed analyst estimates, sending its shares sharply lower.

  • 04/18/2017 09:32:22

    Weak Goldman, J&J results drag down Wall Street

    (Reuters) - U.S. stocks drifted lower on Tuesday as corporate heavyweights Goldman Sachs and Johnson & Johnson disappointed investors with their quarterly results, while geopolitical tensions continued to weigh on market sentiment.

  • 04/18/2017 07:35:52

    Why Johnson & Johnson Raised Guidance After Missing Sales Estimates


  • 03/09/2017 14:06:12

    Stocks close fractionally higher as ECB stands pat on easing

    U.S. stocks finished slightly higher Thursday after European Central Bank President Mario Draghi left easing measures in place but downplayed deflation concerns. The Dow Jones Industrial Average advanced 2.46 points to finish at 20,858.19 led higher by shares of Johnson & Johnson Inc. . The S&P 500 index closed up 1.89 points, or just under 0.1%, at 2,364.87, as health-care and energy stocks gained. The Nasdaq Composite index finished up 1.25 points at 5,838.81.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 03/03/2017 15:01:27

    Johnson & Johnson wins trial in talc product liability lawsuits

    - Johnson & Johnson said on Friday that a state court jury in Missouri had returned a verdict in its favor in the latest trial to arise out of thousands of lawsuits alleging the company's talc-based products can increase the risk of ovarian cancer.

  • More trends:

    Johnson ControlsJCI-0.1% | Jones EnergyJONE+6.19% | Jones Lang LaSalle IncorporatedJLL | Journal Media GroupJMG | Joy Global Inc.JOY | JP Energy Partners LPJPEP | JPMorgan China Region FundJFC | Jumei International Holding LimitedJMEI | Juniper NetworksJNPR | Jupai Holdings LimitedJP |